Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. operates as a contract research organization that provides a broad range of laboratory and preclinical services to the life‑science industry. Its offerings include drug discovery support, safety assessment, pharmacology, toxicology, pathology, and bioanalytical testing, as well as clinical trial services such as central laboratory analysis and biomarker development. The company serves biotechnology firms, pharmaceutical corporations, and medical‑device manufacturers that require outsourced expertise to advance compounds from early‑stage research through regulatory submission. By maintaining facilities in multiple geographic regions, it enables sponsors to access localized scientific talent while benefiting from a unified global quality framework. Its service model is designed to help clients reduce internal overhead, accelerate timelines, and meet stringent regulatory expectations set by agencies such as the FDA and EMA.

Headquartered in the United States of America, Charles River Laboratories is recognized for its deep specialization in regulated preclinical testing, adhering to Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) standards that are essential for IND‑enabling studies. The firm’s longstanding reputation for scientific rigor and compliance has positioned it as a preferred partner for organizations navigating complex drug‑development pathways. While the prompt notes a 2019 incident in which an unauthorized intruder accessed systems and copied data belonging to roughly one percent of its clients, the company responded with an investigation, containment measures, client notification, and enhanced security controls. The compromised data did not include patient information, and there was no evidence of deletion, corruption, or alteration of the accessed information. No further details about ownership or parent‑subsidiary relationships are provided in the source material, so those aspects are not elaborated here.